Investors sentiment increased to 2.09 in 2019 Q2. Its up 0.74, from 1.35 in 2019Q1. It improved, as 7 investors sold Recro Pharma, Inc. shares while 16 reduced holdings. 21 funds opened positions while 27 raised stakes. 12.10 million shares or 8.99% more from 11.11 million shares in 2019Q1 were reported.
Jefferies Group Llc has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Meeder Asset Mgmt Inc invested in 12,895 shares or 0.01% of the stock. Dimensional Fund Advsr Lp reported 0% in Recro Pharma, Inc. (NASDAQ:REPH). Vanguard Group reported 0% stake. Prelude Capital Mgmt Ltd Com reported 0% in Recro Pharma, Inc. (NASDAQ:REPH). Renaissance Technology Llc has invested 0.01% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH). Blackrock Incorporated invested in 0% or 1.29 million shares. California Employees Retirement holds 0% or 64,300 shares. 2,020 were accumulated by Bnp Paribas Arbitrage Sa. Morgan Stanley has 88,135 shares. Jpmorgan Chase & reported 148,946 shares. Voloridge Invest Limited Liability Com has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 14,972 shares. Oppenheimer And Com holds 32,465 shares or 0.01% of its portfolio. State Of Wisconsin Board reported 24,200 shares stake. Ameritas Invest Prns stated it has 1,196 shares or 0% of all its holdings.
The stock of Recro Pharma, Inc. (NASDAQ:REPH) is a huge mover today! The stock decreased 1.24% or $0.21 during the last trading session, reaching $16.66. About 147,771 shares traded. Recro Pharma, Inc. (NASDAQ:REPH) has risen 88.61% since December 4, 2018 and is uptrending. It has outperformed by 88.61% the S&P500.
The move comes after 9 months negative chart setup for the $378.69 million company. It was reported on Dec, 4 by Barchart.com. We have $15.16 PT which if reached, will make NASDAQ:REPH worth $34.08M less.
Analysts await Recro Pharma, Inc. (NASDAQ:REPH) to report earnings on February, 18. They expect $-0.14 earnings per share, up 75.86 % or $0.44 from last year’s $-0.58 per share. After $-0.19 actual earnings per share reported by Recro Pharma, Inc. for the previous quarter, Wall Street now forecasts -26.32 % EPS growth.
More notable recent Recro Pharma, Inc. (NASDAQ:REPH) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings – Benzinga” on November 06, 2019, also Benzinga.com with their article: “Stocks That Hit 52-Week Highs On Friday – Benzinga” published on November 29, 2019, Nasdaq.com published: “BGNE Soars, DRNA Hits New High On Roche Deal, FDA Heeds REPH’s Request – Nasdaq” on November 01, 2019. More interesting news about Recro Pharma, Inc. (NASDAQ:REPH) were released by: Nasdaq.com and their article: “Growing Competition Will Impact Qualcomm Stock in the Medium Term – Nasdaq” published on November 25, 2019 as well as Nasdaq.com‘s news article titled: “Will Third Time Prove A Charm For Baudax Bio? – Nasdaq” with publication date: November 27, 2019.
Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $378.69 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.